{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:57:35Z","timestamp":1763200655239,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2024206056","H2023307028"],"award-info":[{"award-number":["H2024206056","H2023307028"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103475"],"award-info":[{"award-number":["82103475"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Medical Science Research Project of Hebei Provincial Health Commission","award":["20240370"],"award-info":[{"award-number":["20240370"]}]},{"name":"Hebei Province Government-Funded Clinical Medicine Excellent Talent Training Program","award":["ZF2025013"],"award-info":[{"award-number":["ZF2025013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00702-z","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T19:32:47Z","timestamp":1732908767000},"page":"191-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran"],"prefix":"10.1007","volume":"25","author":[{"given":"Yihan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"702_CR1","unstructured":"Sud M, Chu A, Austin PC, et al. Impact of outcome definitions on cardiovascular risk prediction in a contemporary primary prevention population. Eur Heart J Qual Care Clin Outcomes. 2023;9(4):427\u201334."},{"key":"702_CR2","doi-asserted-by":"crossref","unstructured":"Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Eur Heart J. 2020;134:69\u201373.","DOI":"10.1016\/j.amjcard.2020.08.018"},{"issue":"6","key":"702_CR3","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1007\/s12325-021-01741-7","volume":"38","author":"H Tan","year":"2021","unstructured":"Tan H, Liu L, Zheng Q, et al. Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome. Adv Ther. 2021;38(6):3389\u201398.","journal-title":"Adv Ther"},{"issue":"9","key":"702_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","volume":"20","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, et al. 2023 China guidelines for lipid management. J Geriatr Cardiol JGC. 2023;20(9):621\u201363.","journal-title":"J Geriatr Cardiol JGC"},{"key":"702_CR5","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Mu\u00f1oz Estrella A, Sourlas A, et al. Inclisiran: A new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63.","DOI":"10.3390\/diseases6030063"},{"key":"702_CR6","doi-asserted-by":"crossref","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","DOI":"10.1056\/NEJMoa1615758"},{"key":"702_CR7","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","DOI":"10.1136\/bmj.d5928"},{"issue":"2","key":"702_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3904\/kjim.2016.195","volume":"33","author":"YH Lee","year":"2018","unstructured":"Lee YH. An overview of meta-analysis for clinicians. Korean J Intern Med. 2018;33(2):277\u201383.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"702_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351.","journal-title":"N Engl J Med"},{"issue":"20","key":"702_CR10","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, et al. An \u201cInclisiran First\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"702_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Teoh H, Kallend D, et al. Inclisiran Lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173\u20136.","journal-title":"Diabetes Care"},{"issue":"3","key":"702_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","volume":"17","author":"Z Luo","year":"2023","unstructured":"Luo Z, Huang Z, Sun F, et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17(3):392\u2013400.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"702_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7196\/SAMJ.2022.v112i6.16253","volume":"112","author":"F Raal","year":"2022","unstructured":"Raal F, Abelson M, Blignaut S, et al. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: a subanalysis of the ORION phase III clinical trials. Samj S Afr Med J. 2022;112(6):426\u201332.","journal-title":"Samj S Afr Med J"},{"key":"702_CR14","doi-asserted-by":"crossref","unstructured":"Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354\u201362.","DOI":"10.1161\/CIRCULATIONAHA.122.063460"},{"issue":"16","key":"702_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"48","key":"702_CR16","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357.","journal-title":"Eur Heart J"},{"issue":"16","key":"702_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"key":"702_CR18","doi-asserted-by":"crossref","unstructured":"Baigent, C, Keech, A, Kearney, PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. LANCET. 2005; 366 (9493):1267\u201378.","DOI":"10.1016\/S0140-6736(05)67394-1"},{"issue":"10","key":"702_CR19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.33963\/KP.a2023.0147","volume":"81","author":"LS Rallidis","year":"2023","unstructured":"Rallidis LS, Tsamoulis D, Leventis I, et al. Extremely high-risk patients with acute coronary syndrome: how \u201cextreme\u201d should lipid-lowering therapy be if the LDL-C target <40 mg\/dl is considered? Kardiol Pol. 2023;81(10):1012\u20134.","journal-title":"Kardiol Pol"},{"key":"702_CR20","doi-asserted-by":"crossref","unstructured":"Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60\u201368.","DOI":"10.1016\/S0140-6736(13)61914-5"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"8129513","DOI":"10.1155\/2022\/8129513","volume":"2022","author":"I Mer\u0107ep","year":"2022","unstructured":"Mer\u0107ep I, Fri\u0161\u010di\u0107 N, Striki\u0107 D, Reiner \u017d. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-a narrative review. Cardiovasc Ther. 2022;2022:8129513.","journal-title":"Cardiovasc Ther"},{"key":"702_CR22","unstructured":"Six-Month Adherence Among Early Inclisiran Initiators vs. Anti-PCSK9 mAbs Users: a retrospective analysis of US claims databases.\u00a0In: Presented at AHA2023 meeting. Mo3251."},{"key":"702_CR23","doi-asserted-by":"crossref","unstructured":"Cowart K, Singleton J, Carris NW. Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: a narrative review. Clin Ther. 2023;45(11):1099\u2013104.","DOI":"10.1016\/j.clinthera.2023.06.011"},{"key":"702_CR24","doi-asserted-by":"crossref","unstructured":"Wright RS, Koenig W, Landmesser U, et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82(24):2251\u201361.","DOI":"10.1016\/j.jacc.2023.10.007"},{"key":"702_CR25","doi-asserted-by":"crossref","unstructured":"Li J, Lei X, Li Z, Yang X. Effectiveness and safety of Inclisiran in hyperlipidemia treatment: an overview of systematic reviews. Medicine (Baltimore). 2023;102(3):e32728.","DOI":"10.1097\/MD.0000000000032728"},{"key":"702_CR26","doi-asserted-by":"crossref","unstructured":"Brandts J, Dharmayat KI, Vallejo-Vaz AJ, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021;325:46\u201356.","DOI":"10.1016\/j.atherosclerosis.2021.03.042"},{"key":"702_CR27","doi-asserted-by":"crossref","unstructured":"Karakasis P, Patoulias D, Barkas F, et al. Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials. Hellenic J Cardiol. 2024.","DOI":"10.1016\/j.hjc.2024.06.005"},{"key":"702_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.amjcard.2020.05.024","volume":"128","author":"AAA Asbeutah","year":"2020","unstructured":"Asbeutah AAA, Asbeutah SA, Abu-Assi MA. A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran. Am J Cardiol. 2020;128:218\u20139.","journal-title":"Am J Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00702-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00702-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00702-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:28:36Z","timestamp":1739172516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00702-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00702-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"31 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Natural Science Foundation of China (82103475), Hebei Province Natural Science Foundation (H2023307028, H2024206056), the Medical Science Research Project of Hebei Provincial Health Commission (20240370), and Hebei Province Government-Funded Clinical Medicine Excellent Talent Training Program (ZF2025013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yihan Li, Kefan Xue, Rui Hu, Xiao Hu, Ran Guo, Hongxia Gu, and Gang Li declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Yihan Li: conceptualization, methodology, software, investigation, formal analysis, writing \u2013 original draft. Kefan Xue: data curation, writing \u2013 original draft. Rui Hu: visualization, investigation. Xiao Hu: resources, supervision. Ran Guo: software, validation. Hongxia Guo: visualization, writing \u2013 review and editing. Gang Li: conceptualization, funding acquisition, resources, supervision, writing \u2013 review and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}